Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2005 1
2006 4
2007 1
2008 1
2012 3
2013 9
2014 8
2015 18
2016 66
2017 75
2018 115
2019 131
2020 190
2021 246
2022 208
2023 250
2024 285
2025 342
2026 201

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,932 results

Results by year

Filters applied: . Clear all
Page 1
Tenofovir Alafenamide.
Gibson AK, Shah BM, Nambiar PH, Schafer JJ. Gibson AK, et al. Ann Pharmacother. 2016 Nov;50(11):942-952. doi: 10.1177/1060028016660812. Epub 2016 Jul 28. Ann Pharmacother. 2016. PMID: 27465879 Review.
OBJECTIVE: To review the pharmacology, efficacy, safety, and place in therapy for tenofovir alafenamide (TAF). DATA SOURCES: A search using PubMed was conducted (2004 to May 2016) using the following keywords: tenofovir alafenamide, TAF, and GS-7340. . …
OBJECTIVE: To review the pharmacology, efficacy, safety, and place in therapy for tenofovir alafenamide (TAF). DATA SOURCES: A …
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Eke AC, Brooks KM, Gebreyohannes RD, Sheffield JS, Dooley KE, Mirochnick M. Eke AC, et al. Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):333-342. doi: 10.1080/17425255.2020.1738384. Epub 2020 Mar 17. Expert Opin Drug Metab Toxicol. 2020. PMID: 32125906 Free PMC article. Review.
Introduction: Tenofovir alafenamide (TAF)-containing fixed-dose drug combinations (FDCs) are increasingly being used in managing pregnant women living with HIV. ...
Introduction: Tenofovir alafenamide (TAF)-containing fixed-dose drug combinations (FDCs) are increasingly being used in managi …
Tenofovir alafenamide fumarate.
Lee WA, Cheng AK. Lee WA, et al. Antivir Ther. 2022 Apr;27(2):13596535211067600. doi: 10.1177/13596535211067600. Antivir Ther. 2022. PMID: 35499175 Free article.
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its sele …
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue re …
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
Scott LJ, Chan HLY. Scott LJ, et al. Drugs. 2017 Jun;77(9):1017-1028. doi: 10.1007/s40265-017-0754-9. Drugs. 2017. PMID: 28493172 Review.
Tenofovir alafenamide (AF) [Vemlidy( )], an oral prodrug of tenofovir, was developed to optimize the antiviral potency and clinical safety of the active moiety tenofovir diphosphate (selective reverse transcriptase nucleotide inhibitor). ...
Tenofovir alafenamide (AF) [Vemlidy( )], an oral prodrug of tenofovir, was developed to optimize the antiviral potency and cli …
Tenofovir alafenamide nephrotoxicity: a case report and literature review.
Ueaphongsukkit T, Gatechompol S, Avihingsanon A, Surintrspanont J, Iampenkhae K, Avihingsanon Y, Udomkarnjananun S. Ueaphongsukkit T, et al. AIDS Res Ther. 2021 Aug 21;18(1):53. doi: 10.1186/s12981-021-00380-w. AIDS Res Ther. 2021. PMID: 34419091 Free PMC article. Review.
BACKGROUND: Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has become the preferred drug for the treatment of HIV-1 and chronic hepatitis B infection in clinical practice. ...
BACKGROUND: Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has become the preferred drug for the treatment o …
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Viganò M, Loglio A, Grossi G, Lampertico P. Viganò M, et al. Expert Rev Anti Infect Ther. 2018 Feb;16(2):153-161. doi: 10.1080/14787210.2018.1428561. Epub 2018 Jan 23. Expert Rev Anti Infect Ther. 2018. PMID: 29338458 Review.
However, reduced kidney function and loss of bone mineral density have been reported in some CHB patients treated with TDF. Consequent to these safety issues, tenofovir alafenamide (TAF) [Vemlidy ], a phosphonate prodrug of TFV, was developed for the treatment of CH …
However, reduced kidney function and loss of bone mineral density have been reported in some CHB patients treated with TDF. Consequent to th …
Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection.
Childs-Kean LM, Egelund EF, Jourjy J. Childs-Kean LM, et al. Pharmacotherapy. 2018 Oct;38(10):1051-1057. doi: 10.1002/phar.2174. Epub 2018 Sep 9. Pharmacotherapy. 2018. PMID: 30120841 Review.
Tenofovir alafenamide (TAF) is indicated for adult patients with chronic hepatitis B virus (HBV) infection with compensated liver disease at an oral dose of 25 mg/day. ...
Tenofovir alafenamide (TAF) is indicated for adult patients with chronic hepatitis B virus (HBV) infection with compensated li …
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
Abdul Basit S, Dawood A, Ryan J, Gish R. Abdul Basit S, et al. Expert Rev Clin Pharmacol. 2017 Jul;10(7):707-716. doi: 10.1080/17512433.2017.1323633. Epub 2017 May 17. Expert Rev Clin Pharmacol. 2017. PMID: 28460547 Review.
In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB). ...
In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (C …
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.
Andreatta K, Sax PE, Wohl D, D'Antoni ML, Liu H, Hindman JT, Callebaut C. Andreatta K, et al. J Antimicrob Chemother. 2025 Jan 3;80(1):281-291. doi: 10.1093/jac/dkae407. J Antimicrob Chemother. 2025. PMID: 39556192 Free PMC article. Clinical Trial.
OBJECTIVE: Five Phase 3 bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) clinical studies demonstrated that the efficacy of B/F/TAF was non-inferior to dolutegravir (DTG) + 2 NRTIs. ...
OBJECTIVE: Five Phase 3 bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) clinical studies demonstrated that the effic …
1,932 results